The following new article has just been published in Asthma Research and Practice

Juan Carlos Ivancevich Tuesday, 09 February 2016 20:52


Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy

Svedsater H, Stynes G, Wex J, Frith L, Leather D, Castelnuovo E, Detry M, Berry S

Asthma Research and Practice 2016, 2 :4 (8 February 2016)

Abstract | Full Text | PDF

WCA 2016 - Venue and General Information

Juan Carlos Ivancevich Wednesday, 03 February 2016 14:54

Congress Venue

Meliá Castilla

Calle del Capitán Haya, 43

Madrid 28020 



Climate and Dress Code

Madrid and its metropolitan area has a Mediterranean climate with continental influences, with mild cool winters and hot summers. The average temperature in March it varies from +8oC (46oF) to +20oC (60oF). The Spanish capital is in the center of the Iberian Peninsula, 622 meters above sea level. The dress code will be informal throughout the Congress.


The local currency is the Euro (EUR).


The WCA 2016 Congress in Madrid will include an exhibition that will be open from 12-15 March.
For more information regarding the exhibition and other sponsorship opportunities, please visit the Congress website or contact This email address is being protected from spambots. You need JavaScript enabled to view it.


The official language of the Congress is English.

Local Time

The time zone in Madrid is Central European Time (CEST / GMT +1) .


Participants are advised to make their own arrangements with respect to entering Spain.
If you need a letter of invitation, contact This email address is being protected from spambots. You need JavaScript enabled to view it.  after your registration fee is settled.
Please apply for a visa within a reasonable time prior to making your bookings.

Travel and Health Insurance

It is strongly recommended that all participants purchase adequate coverage for health, travel and private liability insurance before departing from their home countries. The Organizers will not accept responsibility for personal injury, loss or damage to private, personal property of participants, accompanying persons and exhibitors.

Asthma in the elderly patient

Juan Carlos Ivancevich Wednesday, 03 February 2016 13:26
Louis-Philippe Boulet

DOI: 10.1186/s40733-015-0015-1


Asthma affects a significant proportion of elderly patients, but unfortunately, it is responsible for a high asthma-related morbidity and mortality in this population. This may be related not only to the development of a more severe asthma phenotype compared to younger patients, with more marked airway obstruction and a more neutrophilic type of airway inflammation, but also to the presence of many co-morbid conditions. Furthermore, in older patients, asthma is often under-diagnosed, undertreated and poorly managed. Unfortunately, elderly patients have usually been excluded of clinical trials on asthma and there is an urgent need to perform more research on the optimal management of asthma in this population.

Table of Contents

World Congress of Astma, Madrid March 12-15, 2016: Scientific Program Committee´s Message

Juan Carlos Ivancevich Friday, 29 January 2016 13:42

Significant achievements have been accomplished in the last few years to better understanding what is asthma, how it should be assessed in regard to control and severity and what is its optimal therapy. Unfortunately these improvements in our understanding of the disease have not always translated into better asthma management.

The 2016 World Congress on Asthma in Madrid will review the key findings from recent research on both adult and pediatric Asthma and how knowledge translation methods have evolved to better integrate research findings into care.

The origins and determinants of Asthma, triggers and inducers, the new insight gained on the role of allergy, environmental and biodiversity changes, workplace hazards, respiratory infections andvarious aspects of assessment of the disease are among the topics that will be covered by world experts. The role of phenotyping/endotyping Asthma, particularly when severe, and new therapeutic current and future advances will be covered.

A significant part of the meeting will be devoted to practical workshops on asthma testing and treatment delivery, as we'll as the integration of practice tools into day-to-day care. Sessions will discuss how to optimize the multidisciplinary approach to asthma management.

We and the members of the scientific advisory board the impressive program of WCA-2016 will be of interest to all those involved in research and care of asthma.

G. Walter Canonica   Lawrence DuBuske   Louis-Philippe Boulet   Ralph Mösges


on behalf of the Scientific Programme Committee –WCA 2016 Madrid INTERASMA

WCA 2016 - Scientific Program Saturday March 12, 2016

Juan Carlos Ivancevich Wednesday, 13 January 2016 03:55
  Room A
Room B
Room C


ACOS Symposium

Chairs: Stefano Centanni, Joan Soriano 

Marc Miravitlles “ACOS-The Spanish document”
Vito Brusasco “Do we need ACOS?” 

Mar Fernandez- Nieto Eosinophilic bronchitis”

SEPAR Symposium

Chairs: Inmaculada Alfageme,  Carlos Melero

Antolín Lopez-Viña“Novedades terapeuticas de la guia española para el manejo del asma GEMA 4.0”
Eva Martinez Moragon“Asma y embarazo: dos escenarios para cuidar” 
Luis Perez de Llano“Coexistencia de asma y EPOC”
"Basic Science in Asthma & Related Disorders"

Chairs: Giovanni Passalacqua, Carlos Nunes 

David Soto “The role of stem cells in asthma: pathogenic versus therapeutic”
Alberto Papi “Virus and Asthma” 
Santiago Quirce“Neutrophilic Inflammation in Asthma”









16.00 Coffee Break


Social Aspects of Respiratory Diseases (GARD Session)

Chairs: Nikolai Khaltaev, G.Walter Canonica 

Nikolai Khaltaev “Social Predictors of Health (GARD Perspective)"
Arzu Yorgancıoğlu "Social determinants of obstructive diseases other than tobacco"

Alvaro Cruz “Do socieconomic inequalities in health have an impact on Asthma and Allergic diseases?”

Jaime Correia de Sousa “The role of primary care in dealing with social determinants”

SEAIC Symposium

Chairs: TBA

Mar Fernandez-Nieto “New developments in occupational asthma”
Irina Bobolea “Clinical Management of aspirin-exacerbated respiratory disease” 
Silvia Sanchez-Garcia“Childhood Asthma: Role of alergens”
Workshop:"Diet and Lifestyle"

Chairs: Carlo Lombardi, Ruby Pawankar 

Catherine Hawrylowicz“Vitamin D and Corticosteroid Response”
Sergio Bonini “Regulatory aspects of anti-asthmatic drugs” 
Jonathan Bernstein“Occupational Asthma”





Keynote Lecture

  Joaquin Sastre, Inmaculada Alfageme, G.Walter Canonica

Kian Fan Chung
"Systems Medicine as Pathway to Precision Medicine"


Opening Ceremony


Poster Discussion

The geriatric asthma: pitfalls and challenges

Juan Carlos Ivancevich Thursday, 07 January 2016 05:09

Alida Benfante and Nicola Scichilone


Historically, asthma has been envisioned as a disease of younger ages. This has led to the assumption that respiratory symptoms suggestive of asthma occurring in older ages are to be attributed to conditions other than asthma, mainly COPD. Old observational reports and new epidemiological studies confirm that asthma is as frequent in older as it is in younger populations. Nevertheless, under-recognition, misdiagnosis and under-treatment are still relevant issues. The characterization of asthma in the aged suffers from the fact that there has been very little original research in this field. Indeed, geriatric asthma is often excluded from clinical trials because of age and comorbidities. The current review paper revises the areas that need to be elucidated, and highlights the gaps in the management of this condition. It follows that a multidimensional management is advocated for elderly asthmatics to evaluate the severity and establish the complexity of the disease. We suggest that the term “geriatric” asthma should be preferred to “senile” asthma, which is confined to the age-related changes in the lung, or the more generic “asthma in the elderly”, which is only descriptive of the prevalence in specific age groups.

Download PDF



Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics

Juan Carlos Ivancevich Wednesday, 06 January 2016 13:12

DOI: 10.1186/s40733-015-0019-x



In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with a greater risk of exacerbation.


Fifteen outpatients with moderate allergic asthma were recruited. Serum concentrations of periostin were assessed (ELISA) at baseline, and the frequency of asthma exacerbations was recorded during a one-year follow-up.


Patients (M/F: 10/5, mean age of 47.6 ± 11.0 years) had mean ACQ score of 5.5 ± 4.2 and FEV1%pred of 81.9 ± 21.7 %. Baseline serum levels of periostin did not correlate with lung function parameters, nor with the ACQ score (p ≥0.05 for all analyses). Five subjects (33 % of the study group) reported one or more exacerbations during the following year. Baseline serum levels of periostin were significantly higher in subjects who experienced one or more exacerbations during the one year period of follow-up, compared with subjects with no exacerbations: median serum periostin level was 4047 ng/ml (range: 2231 to 4889 ng/ml) and 222 ng/ml (range 28.2 to 1631 ng/ml) respectively; p = 0.001.


The findings of the present pilot study could form the basis for the design of larger studies aiming at developing strategies to identify asthmatic patients at risk for exacerbations.

Download PDF

The WEB-based Asthma Control: an intriguing connection or a dangerous hazard?

Juan Carlos Ivancevich Tuesday, 29 December 2015 03:09

Carlo Lombardi, Giovanni Passalacqua and Giorgio Walter Canonica


Globally, an estimated 300 million people have asthma, presenting a considerable and increasing burden of disease for healthcare systems, families, and patients themselves. Despite two decades of guidelines, asthma seems to remain not optimally controlled in a substantial proportion of people. The achievement of asthma control is the result of the interaction among different variables concerning the disease pattern and patients’ and physicians’ knowledge and behavior. It is well known that adherence to treatment increases in parallel to patient education. There is now a growing interest in the use of digital information technologies to promote asthma control and improve outcomes. Mobile health, or mHealth, refers to mobile devices, medical sensors, and communication technologies that can enhance chronic disease care and monitoring. Aim of this review was to evaluate the web resources nowadays available and to analyze the published studies about the web-based instruments used to improve asthma knowledge, control asthma outcomes. In general, studies revealed that the technology is well accepted. Interactive asthma technology may be, in addition, of help in reaching populations difficult to reach, such as inner city populations. The number of tools and apps available continues to increase, and agencies such as the FDA, become involved in their regulation, thus the mHealth landscape will continue to evolve. Although asthma tools and apps have great potential to improve care for asthma, the proof of data reproducibility, the demonstration of effectiveness, and the privacy issues still represent the major technical problems.


Asthma control Asthma knowledge Patient behavior Internet engines Social network Apps

The WCA-2016 Board wishes you Happy Holidays and a productive & prosperous New Year!

Juan Carlos Ivancevich Monday, 21 December 2015 23:26

Sickle cell disease: wheeze or asthma?

Juan Carlos Ivancevich Wednesday, 09 December 2015 12:17
  • Robyn T. Cohen, Elizabeth S. Klings and Robert C. Strunk


Sickle cell disease (SCD) is the most common life-limiting genetic disease among African Americans, affecting more than 100,000 people in the United States. Respiratory disorders in patients with sickle cell disease have been associated with increased morbidity and mortality. Associations between asthma and pain, acute chest syndrome (ACS), and even death have long been reported. More recently wheezing, even in the absence of an asthma diagnosis, has gained attention as a possible marker of SCD severity. Several challenges exist with regards to making the diagnosis of asthma in patients with SCD, including the high prevalence of wheezing, evidence of airway obstruction on pulmonary function testing, and/or airway hyperresponsiveness among patients with SCD. These features often occur in isolation, in the absence of other clinical criteria necessary for an asthma diagnosis. In this review we will summarize: 1) Our current understanding of the epidemiology of asthma, wheezing, airway obstruction, and airway responsiveness among patients with SCD; 2) The evidence supporting associations with SCD morbidity; 3) Our understanding of the pathophysiology of airway inflammation in SCD; 4) Current approaches to diagnosis and management of asthma in SCD; and 5) Future directions.


Table of Contents


Interasma on Twitter

Interasma Top story: European Academy of Allergy and Clinical Immunology calls for improved food allergy labelling to protect…
Interasma RT @Aller_MD: My Tweeted Times - top stories by @DrLindaMD, @GavinPrestonMD
Interasma RT @Aller_MD: Top story: Percentage of young U.S. children who don’t receive any vaccines has quadrupled since 2001 - The Washington Post h…
Interasma RT @ProfGRoberts: European Academy of Allergy and Clinical Immunology calls for improved food allergy labelling to protect consumers with f…

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA